-
Results from a Phase 3 study of dabigatran, intensive lipid-lowering in CVD, H1N1 vaccine dosing and efficacy, and FDA Actions
-
In a retrospective review of 71 patients treated in either a second- or third-line setting for small-cell lung cancer (SCLC) at a single institution, three orally administered drugs (lomustine, etoposide, and cyclophosphamide) were shown to be effective in producing responses (overall response rate 38%) but had little effect on overall survival (median survival 19 weeks).
-
Among funeral workers, the duration of embalming practice and related formaldehyde exposure were significantly associated with an increased risk for mortality from myeloid leukemia.
-
-
In this pooled analysis of more than 7700 ovarian cancer patients and nearly 12,000 controls, low dose aspirin and high dose non-aspirin NSAID use was associated with a risk reduction for invasive epithelial ovarian cancer of 20 to 34% relative to non-users.
-
In a nested, case-control analysis using a large computerized clinical dataset, a 16% reduction in colorectal cancer incidence was observed after 3 or more years of angiotensin inhibitor and/or angiotensin receptor blocker treatment of hypertension.
-
After a median follow-up of 5 years, the aromatase inhibitor, anastrozole decreased the incidence of breast cancer in high-risk postmenopausal women by 53% compared to women receiving a placebo.
-
Synopsis: In this study, the authors evaluated and refined previously published risk stratification for locoregional failure (LF) by applying it to a multicenter patient cohort.
-
In a trial comparing chemotherapy alone to chemotherapy plus bevacizumab in the treatment of patients with platinium-resistant ovarian cancer, the combination resulted in improved response rates and progression-free survival (PFS) and without a high rate of added toxicity. Whether bevacizumab alone would provide comparable improvements was not assessed but remains an important question for future trials.
-
In an international, randomized, non-inferiority trial, bendamustine-rituximab proved comparable in overall response rate when compared with R-CHOP or R-CVP in the management of indolent NHL and mantle cell lymphoma. Progression free and overall survival comparisons remain to be determined. Notably, toxicity profiles were significantly different, with higher rates of reported nausea and vomiting with BR and neuropathy and alopecia with R-CHOP/R-CVP.
